IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

561.73
CHF
+123.22
(+28.10%)
12.37EPS
Feb 08Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.95
14.84
17.3
19.79
22.43
25.48
27.95
31.72
37.74
40.27
44.07
47.26
53.51
58.77
Basic EPS, GAAP
1.77
1.82
2.07
2.47
3
4.34
4.97
6.82
8.74
8.12
10.17
10.77
13.17
14.9
Free Cash Flow per Basic Share
1.57
1.75
1.5
3.06
3.38
3.19
3.53
6.33
7.46
4.59
9.3
9.68
12.98
16.39
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
5.03
1.24
-0.93
-1.23
-0.62
-0.11
2.08
7.4
8.16
7.34
17.88
19.55
20.14
23.72
Tangible Book Value per Share
2.7
-1.39
-3.54
-3.78
-3.42
-3.09
-1.41
3.93
2.74
1.8
12.45
13.22
13.57
14.1
Basic Weighted Avg Shares
106
100
93
90
88
87
86
85
85
84
83
82
80
79
Sales/Revenue/Turnover
1,377
1,486
1,602
1,775
1,969
2,213
2,407
2,707
3,215
3,367
3,661
3,898
4,304
4,662
Operating Margin (%)
19.37
17.52
19.24
19.73
20.98
22.2
22.97
25.66
28.99
26.69
29.97
28.95
31.6
32.3
Depreciation Expense
55
59
69
78
83
83
88
96
105
112
115
130
145
158
Net Income, GAAP
188
182
192
222
263
377
428
582
745
679
845
888
1,059
1,182
Effective Tax Rate (%)
28.67
26.2
29.66
31.01
30.91
17.63
18.08
12.06
17.48
21.03
20.37
20
19.99
20.07
Profit Margin (%)
13.64
12.24
11.99
12.51
13.36
17.04
17.77
21.49
23.17
20.17
23.08
22.78
24.62
25.36
Working Capital
174
-62
-35
-89
-33
-116
-46
480
192
-134
544
332
265
236
LT Debt
150
350
597
593
606
601
766
936
863
796
723
548
476
397
Total Equity
518
118
-84
-108
-54
-9
178
633
690
609
1,485
1,595
1,605
1,869
Return on Invested Capital (%)
20.88
19.2
19.71
21.82
24.31
36.05
39.57
41.44
44.85
36.61
36.8
34.32
41.13
42.49
Return on Capital (%)
21.33
19.69
20.22
22.38
25.07
36.9
40.47
42.34
45.84
37.4
37.93
35.56
42.24
43.86
Return on Common Equity (%)
32.54
57.23
- -
- -
- -
- -
- -
143.73
112.68
104.58
80.74
57.66
66.2
68.93

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
707
696
576
LT Borrowings
300
300
300
LT Finance Leases
99
101
98
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
79
79
79
Market Capitalization
47,415
44,097
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,454
1,509
1,500
Cash, Cash Equivalents & STI
201
197
198
Accounts Receivable, Net
604
627
616
Inventories
382
392
391
Total Current Liabilities
1,300
1,288
1,264
Payables & Accruals
412
397
438
ST Debt
707
696
576
Deferred Revenue
36
36
40

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-172.52%
29.84%
0.63%
Free Cash Flow
29.98%
22.67%
30.76%
Net Income, GAAP
19.49%
13.61%
19.33%
Sales/Revenue/Turnover
10.45%
9.82%
10.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
964
1,004
976
954
3,898
2025
998
1,109
1,105
1,091
4,304
2026
1,141
1,217
1,214
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.84
2.46
2.83
2.64
10.77
2025
2.98
3.66
3.43
3.11
13.17
2026
3.5
4.29
4.02
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Michael Erickson
Full Time Employees
11,000
Sector
Health technology
Industry
Medical specialties
Address
One IDEXX Drive Westbrook ME United States 04092
IPO Date
Jun 21, 1991
Website
idexx.com
Business
IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes diagnostic products, equipment, and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. The company offers an extensive portfolio of in-clinic analyzers including the Catalyst One Chemistry Analyzer, ProCyte Dx Hematology Analyzer, SediVue Dx Urine Sediment Analyzer, and SNAP point-of-care tests; reference laboratory services for advanced diagnostics; veterinary software solutions such as IDEXX Neo and Cornerstone practice management software, VetLab Station laboratory information management system, and client communication tools; diagnostic imaging systems like ImageVue DR50 and EliteVision; and specialized tests for ruminants (e.g., BVDV, IBR/BHV-1, Johne's Disease), poultry (e.g., IBV, IBD), swine (e.g., PRRS, PEDV), equine health (e.g., EHV-1/4 RealPCR, EPM tests), and water quality microbiological detection serving over 2.5 billion people. IDEXX also provides OPTI Medical Systems for human point-of-care and laboratory diagnostics. Founded in 1983 and headquartered in Westbrook, Maine, the company operates in over 175 countries through its three main segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD), with additional EMEA headquarters in Hoofddorp, Netherlands, and approximately 10,000 employees worldwide. Recent developments include the strong adoption of the inVue Dx Cellular Analyzer with over 2,400 units installed in Q2 2025, surpassing expectations and prompting a full-year installation forecast increase to 5,500 units; the June 2025 launch of the Catalyst Cortisol Test, the third Catalyst platform expansion that year, enhancing point-of-care diagnostics for endocrine disorders like Addison's and Cushing's disease in dogs; the North American rollout of IDEXX Cancer Dx; upward revisions to 2025 revenue guidance to $4.27 billion-$4.30 billion and EPS to $12.81-$13.01 amid 11% Q2 revenue growth and 13% Q3 growth driven by recurring CAG diagnostics; and sustained R&D investment at about 5.75% of revenue to support platform expansions, AI-driven solutions, molecular tests, international commercial footprint growth in three countries by 2026, and software enhancements.

Company News

  • IDEXX Laboratories, Inc. $IDXX Stock Sold by Eurizon Capital SGR S.p.A.

  • Allspring Global Investments Holdings LLC Sells 1,583 Shares of IDEXX Laboratories, Inc. $IDXX

  • IDEXX Laboratories (NASDAQ:IDXX) Stock: Insider Michael Lane Sells 3,979 Shares

  • IDEXX Laboratories (NASDAQ:IDXX) Stock: Insider Sharon Underberg Sells 8,906 Shares

  • 3 Reasons Growth Investors Will Love Idexx (IDXX)

  • IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)

  • IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class

  • Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors

  • IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund

  • IDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript

  • Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic

  • IDEXX raises forecast, betting diagnostics can offset weak vet visits

  • IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction

  • IDEXX Laboratories Q3 Earnings Call Highlights

  • Idexx (IDXX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

  • IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market

  • IDEXX Laboratories, Perion Network, TAT Technologies And Other Big Stocks Moving Higher On Monday

  • Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates

  • IDEXX Laboratories Announces Third Quarter Results

  • Gear Up for Idexx (IDXX) Q3 Earnings: Wall Street Estimates for Key Metrics